- Trials with a EudraCT protocol (218)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
218 result(s) found for: Negative Staining.
Displaying page 1 of 11.
EudraCT Number: 2017-003505-17 | Sponsor Protocol Number: CRO-17-134,CB-17-01-15 | Start Date*: 2018-01-30 | |||||||||||
Sponsor Name:COSMO TECHNOLOGIES LTD | |||||||||||||
Full Title: Colonic lesion staining and flagging efficacy of methylene blue administered as MMX® 25 mg modified release tablets to patients receiving a split dose regimen of bowel cleansing preparation for col... | |||||||||||||
Medical condition: Patients undergoing a screening or surveillance colonoscopy to detect colonic lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018441-61 | Sponsor Protocol Number: 637 | Start Date*: 2010-12-02 |
Sponsor Name:Dr. Gerhard Mann chem.-pharm. Fabrik GmbH/ Bausch & Lomb Incorporated | ||
Full Title: A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter, Exploratory Study Assessing Safety and Efficacy of BOL-303242-X | ||
Medical condition: Dry eyes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-001471-23 | Sponsor Protocol Number: UZBRU_VHH2_1 | Start Date*: 2019-02-06 |
Sponsor Name:UZ Brussel | ||
Full Title: Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associa... | ||
Medical condition: Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024254-11 | Sponsor Protocol Number: CF101-301KCS | Start Date*: 2011-03-30 | |||||||||||
Sponsor Name:Can-Fite BioPharma, Ltd | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Dry Ey... | |||||||||||||
Medical condition: Moderate-to-severe Dry Eye disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003465-18 | Sponsor Protocol Number: BCT1902 | Start Date*: 2021-10-06 |
Sponsor Name:Breast Cancer Trials | ||
Full Title: A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in e... | ||
Medical condition: Early stage triple negative breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002637-15 | Sponsor Protocol Number: APL2-C3G-204 | Start Date*: 2020-12-22 |
Sponsor Name:Apellis Pharmaceuticals, Inc. | ||
Full Title: AN OPEN-LABEL, RANDOMIZED, CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PEGCETACOPLAN IN THE TREATMENT OF POST-TRANSPLANT RECURRENCE OF C3G OR IC‑MPGN | ||
Medical condition: complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) NL (Ongoing) ES (Ongoing) FR (Completed) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012446-23 | Sponsor Protocol Number: 192371-016 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:Allergan Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 months ... | |||||||||||||
Medical condition: Atopic Keratoconjunctivitis is a bilateral, inflammatory external ocular disease. A serious disease driven by chronic inflammation of the cornea, conjunctiva and lower lid. AKC is commonly presen... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) CZ (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022313-25 | Sponsor Protocol Number: CL-503012 | Start Date*: 2011-01-17 | |||||||||||
Sponsor Name:A.T. Development Switzerland SARL | |||||||||||||
Full Title: International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA™ in Preventing Renal Function Decline in Patients With AA Amyloidosis | |||||||||||||
Medical condition: Renal Function Decline in Patients With AA Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SE (Completed) GB (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed) BG (Completed) PT (Completed) LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002238-35 | Sponsor Protocol Number: 11002X-001 | Start Date*: 2012-10-04 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of an Investigational Eye Drop Formulation with OPTIVE™ Unit-Dose for 3 Months in Subjects with Dry Eye Disease | |||||||||||||
Medical condition: Dry Eye Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004269-14 | Sponsor Protocol Number: HP002-001 | Start Date*: 2018-05-07 |
Sponsor Name:Hamlet Pharma AB | ||
Full Title: A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery | ||
Medical condition: Non-muscle invasive bladder cancer awaiting transurethral surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004970-24 | Sponsor Protocol Number: 2012-004970-24 | Start Date*: 2013-04-19 | |||||||||||
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | |||||||||||||
Full Title: Virological and immunological safety of a dose reduction strategy antiretroviral regimen with efavirenz / tenofovir / emtricitabine | |||||||||||||
Medical condition: HIV -1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003042-16 | Sponsor Protocol Number: IIBSP-PTE-2018-35 | Start Date*: 2019-02-08 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane... | ||
Medical condition: Pterigyum | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004691-37 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT |
Sponsor Name:St Vincents University Hospital | ||
Full Title: Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients. | ||
Medical condition: Psoriasis and Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002279-16 | Sponsor Protocol Number: EOGBM1-18 | Start Date*: 2020-01-02 | |||||||||||
Sponsor Name:Enterome | |||||||||||||
Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe... | |||||||||||||
Medical condition: Progressive or recurrent Glioblastoma (PG) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001725-24 | Sponsor Protocol Number: CTKI258AIC02 | Start Date*: 2011-10-03 | |||||||||||
Sponsor Name:Novartis Pharma Services | |||||||||||||
Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib | |||||||||||||
Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000634-35 | Sponsor Protocol Number: CB-17-01/08 | Start Date*: 2013-05-11 | |||||||||||
Sponsor Name:Cosmo Technologies Ltd. | |||||||||||||
Full Title: Effect of oral administration of Methylene Blue MMX® tablets on double-stranded DNA damage assessed by γH2AX analysis of colon biopsy samples | |||||||||||||
Medical condition: Out-patients of both sexes scheduled for a screening or surveillance colonoscopy and identified as having the clinical requirement for a second colonoscopy within 2 weeks of the initial colonoscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000283-28 | Sponsor Protocol Number: IB_2013–01 | Start Date*: 2013-11-13 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study | |||||||||||||
Medical condition: Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002189-34 | Sponsor Protocol Number: HLX11-BC301 | Start Date*: 2022-10-26 | ||||||||||||||||
Sponsor Name:Shanghai Henlius Biotech, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Pertuzumab Biosimilar HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy o... | ||||||||||||||||||
Medical condition: HER2-Positive and HR-Negative Early-stage or Locally advanced Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002478-29 | Sponsor Protocol Number: CA224-063 | Start Date*: 2019-11-27 | |||||||||||
Sponsor Name:University Hospital Essen | |||||||||||||
Full Title: Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung) | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005200-19 | Sponsor Protocol Number: I-CONIC | Start Date*: 2022-05-09 |
Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken | ||
Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC" | ||
Medical condition: Early Triple Negative Breast Cancer planned for surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.